X

Trial Profile

Retrospective-prospective blinded evaluation predicting efficacy of epirubicin by a multigene assay in advanced breast cancer patients.

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 09 Jun 2017

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Epirubicin (Primary)
Indications Advanced breast cancer
Focus Diagnostic use

Most Recent Events

09 Jun 2017 According to a Medical Prognosis Institute media release, data from this trial presented at the 2017 Annual meeting of American Society of Clinical Oncology (ASCO).
09 Jun 2017 New trial record
04 Jun 2017 Results (n=137) from this trial published in a Medical Prognosis Institute Media Release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com